Category: Global Health

   The idea that the prevalence of disease in developing nations can be reversed with sufficient aid – or by dismantling intellectual property protections for medical innovations - is one that is not often questioned among donor groups based in wealthy nations.

   But the reliance on stopgap funding or undermining patents that provide companies with an incentive to bring lifesaving new drugs to market does not provide a sustainable approach to solving the problems of government corruption, underinvestment in public health infrastructure, and disease control and prevention that cripple developing nations. There are more effective approaches available that have the potential to greatly alleviate the suffering of the world's poor by encouraging the rule of law, economic development, and responsible governance. Donor funds should reserved for true "market failures"; for instance, basic research into vaccines or other treatments for diseases that have little or no market in developed nations.

[Spotlight] [Commentary] [Research] [Events] [News]





  • Are We Doing Enough to Prevent Bioterrorism?, Center for Medical Progress Forum, Speaker(s): Ken Alibek, M.D., Ph.D., Sc.D., May 2003
  • Winning the War Against Bioterrorism: The Role of Private Companies, Manhattan Institute Panel Discussion, Speaker(s): Robert Goldberg, Ph.D., Peter Hotez, M.D, Ph.D., Michael Moodie, Robert Erwin, Ph.D., Lance Gordon, Ph.D., December 2001
  • The Campaign to Fight AIDS: Ensuring Access to the Best Medicines, Center for Medical Progress Forum, Speaker(s): Robert Goldberg, Ph.D., Dr. Scott Gottlieb, Jerry Norris, Dr. Robert Orina Nyarango, Dr. S.L. Ramotlhwa, Dr. Amir Attaran, Karen Bush, Ph.d., Dr. Emilio Emini, Frank R. Lichtenberg, Dr. Mark Dybul, June 2004
    Transcript Available


Project FDA.

home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000